Search
Shandong Province has unveiled an ambitious action plan aimed at stabilizing foreign investment by 2025. The plan underscores support for foreign pharmaceutical companies to engage in segmented production of biological products under qualifying circumstances, while encouraging them to conduct clinical trials for overseas-listed cell and gene therapy medications within Shandong. Additionally, the strategy introduces an innovative "three-channel" approval process — encompassing rapid, conventional, and expedited pathways — for applications seeking to relocate the production of overseas-listed drugs to Shandong. Furthermore, it advocates for the ongoing establishment of a streamlined green channel for the online registration of innovative drugs, ultimately accelerating the market entry of foreign pharmaceutical enterprises' innovative products.
-
C114 Communication Network -
Communication Home
